Compile Data Set for Download or QSAR
Report error Found 106 Enz. Inhib. hit(s) with all data for entry = 11760
TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603933(CHEMBL5208082 | US11873292, Compound A58)
Affinity DataIC50: 8.72nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645383(Trans-biphenyl-4-yl(5-(2-(piperidin- 4-ylmethylami...)
Affinity DataIC50: 10.2nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603929(CHEMBL5201504 | US11873292, Compound A45)
Affinity DataIC50: 15.2nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603930(CHEMBL5174650 | US11873292, Compound A54)
Affinity DataIC50: 15.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603918(CHEMBL5206450 | US11873292, Compound A21)
Affinity DataIC50: 17.1nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645359(trans-N-(4- piperidinyl)-2-(1-(phenylsulfonyl) ind...)
Affinity DataIC50: 22.8nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603911(CHEMBL5170011 | US11873292, Compound A14)
Affinity DataIC50: 24.4nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603916(CHEMBL5170567 | US11873292, Compound A20)
Affinity DataIC50: 25nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645384(Trans-(5-(2-(piperidin-4-ylmethylamino) cyclopropy...)
Affinity DataIC50: 25.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645390(Trans-3-methoxy-1-(5-(2-(piperidin- 4-ylmethylamin...)
Affinity DataIC50: 26.9nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603920(CHEMBL5205837 | US11873292, Compound A32)
Affinity DataIC50: 28.2nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603922(CHEMBL5181753 | US11873292, Compound A38)
Affinity DataIC50: 28.8nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603931(CHEMBL5196436 | US11873292, Compound A53)
Affinity DataIC50: 29.9nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603921(CHEMBL5191047 | US11873292, Compound A33)
Affinity DataIC50: 33.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645379(trans-N-(piperidin-4-ylmethyl)-2- (1-(propylsulfon...)
Affinity DataIC50: 33.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645386(Trans-benzyl-5-(2-(piperidin-4- ylmethylamino)cycl...)
Affinity DataIC50: 35.3nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603923(CHEMBL5172252 | US11873292, Compound A39)
Affinity DataIC50: 38.2nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603915(CHEMBL5191605 | US11873292, Compound A16)
Affinity DataIC50: 38.9nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603924(CHEMBL5196564 | US11873292, Compound A35)
Affinity DataIC50: 39.5nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603927(CHEMBL5191876 | US11873292, Compound A42)
Affinity DataIC50: 41.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603926(CHEMBL5174599 | US11873292, Compound A40)
Affinity DataIC50: 42.5nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645374(trans-N-(piperidin-4-ylmethyl)-2- (1-(4-(trifluoro...)
Affinity DataIC50: 43.3nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603934(CHEMBL5204790 | US11873292, Compound A49)
Affinity DataIC50: 43.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603928(CHEMBL5194745 | US11873292, Compound A43)
Affinity DataIC50: 47.5nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603919(CHEMBL5175125 | US11873292, Compound A24)
Affinity DataIC50: 48.6nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603932(CHEMBL5184995 | US11873292, Compound A55)
Affinity DataIC50: 50.3nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603917(CHEMBL5197243 | US11873292, Compound A17)
Affinity DataIC50: 62.2nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645363(trans-N1-(2-(1-(phenylsulfonyl) indolin-5-yl)cyclo...)
Affinity DataIC50: 62.9nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645362(trans-4-((2-(1-(phenylsulfonyl) indolin-5-yl)cyclo...)
Affinity DataIC50: 68.2nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645369(Trans-tert-butyl 4-((2-(1-(phenylsulfonyl)indolin-...)
Affinity DataIC50: 71.3nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645356(trans-N-(3-indolylmethylene)-2-(1- (phenylsulfonyl...)
Affinity DataIC50: 85.1nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603913(CHEMBL5188749 | US11873292, Compound A3)
Affinity DataIC50: 164nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603912(CHEMBL5177765 | US11873292, Compound A10)
Affinity DataIC50: 223nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603914(CHEMBL5176847 | US11873292, Compound A6)
Affinity DataIC50: 261nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645370(Trans-benzyl 4-((2-(1-(phenylsulfonyl)indolin-5- y...)
Affinity DataIC50: 265nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603910(CHEMBL5200994 | US11873292, Compound A7)
Affinity DataIC50: 334nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603909(CHEMBL5196822 | US11873292, Compound A5)
Affinity DataIC50: 354nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50158869(CHEMBL3786182 | US10836743, Compound GSK-2879552 |...)
Affinity DataIC50: 404nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645368(Trans-4-((4-((2-(1-(phenylsulfonyl)) indolin-5-yl)...)
Affinity DataIC50: 461nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645367(Trans-tert-butyl 4-((4-((2-(1-(phenylsulfonyl))ind...)
Affinity DataIC50: 534nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645371(Trans-tert-butyl 4-(2-(1-(phenylsulfonyl)indolin-5...)
Affinity DataIC50: 1.69E+3nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645351(Trans-2-(1-(phenylsulfonyl)indolin- 5-yl)cycloprop...)
Affinity DataIC50: 1.79E+3nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603927(CHEMBL5191876 | US11873292, Compound A42)
Affinity DataIC50: 3.14E+3nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645383(Trans-biphenyl-4-yl(5-(2-(piperidin- 4-ylmethylami...)
Affinity DataIC50: 7.33E+3nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603917(CHEMBL5197243 | US11873292, Compound A17)
Affinity DataIC50: 9.22E+3nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM645386(Trans-benzyl-5-(2-(piperidin-4- ylmethylamino)cycl...)
Affinity DataIC50: 1.07E+4nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603919(CHEMBL5175125 | US11873292, Compound A24)
Affinity DataIC50: 1.59E+4nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603917(CHEMBL5197243 | US11873292, Compound A17)
Affinity DataIC50: 1.62E+4nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603929(CHEMBL5201504 | US11873292, Compound A45)
Affinity DataIC50: 3.29E+4nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50603921(CHEMBL5191047 | US11873292, Compound A33)
Affinity DataIC50: 3.55E+4nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 106 total ) | Next | Last >>
Jump to: